Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 12/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10965627 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10PIM1POLB | |
| SCHEMBL10960826 | 0.84 | DHFR (0.61) | ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL10960821 | 0.84 | DHFR (0.61) | ALDH1A1HPGDHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL25167945 | 0.82 | PIM1 (0.48) | HPGDHSD17B10PIM1DHFRPIK3CG | |
| SCHEMBL25167944 | 0.82 | PIM1 (0.48) | HPGDHSD17B10PIM1DHFRPIK3CG | |
| SCHEMBL9537269 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10POLBKMT2A | |
| SCHEMBL9537276 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10POLBKMT2A | |
| SCHEMBL10963943 | 0.74 | DHFR (0.65) | DHFR | |
| SCHEMBL11439137 | 0.74 | DHFR (0.65) | DHFR | |
| SCHEMBL9535793 | 0.73 | ALDH1A1 (0.40) | ALDH1A1HPGDHSD17B10PIM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| EP-0006123-B1 | A PTERIDINE DERIVATIVE AND A PROCESS FOR THE PREPARATION OF 10-DEAZAAMINOPTERIN AND ITS DERIVATIVES FROM THE PTERIDINE DERIVATIVE | Southern Research Institute (US) | 1985-01-16 | — | — | EP | disclosed |
| EP-0006123-A1 | A pteridine derivative and a process for the preparation of 10-deazaaminopterin and its derivatives from the pteridine derivative | Southern Research Institute (US) | 1980-01-09 | — | — | EP | disclosed |
| US-4172200-A | MULTISTEP FROM 6-BROMOMETHYL-2,4-PTERIDINEDIAMINE HYDROBROMIDE | SOUTHERN RESEARCH INSTITUTE (US) | 1979-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ALDH1A1 1219/4885HPGD 1595/4885HSD17B10 1209/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ALDH1A1 1219/4885HPGD 1595/4885HSD17B10 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.